Lungs and breathing
127 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| 16-hour PP for acute lung injury | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| a wake prone positioning for respiratory distress syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| a wake prone positioning for respiratory insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Air cleaner for pulmonary disease, chronic obstructive | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Anti Thymocyte Globulin + GM-CSF + Total Body Irradiation + ALEMTUZUMAB + RITUXIMAB + HUMAN IMMUNOGLOBULIN G + Cyclophosphamide + THIOTEPA + Mesna for lung diseases, interstitial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Apps for respiratory insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Apremilast for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Apremilast for respiratory insufficiency | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Atibuclimab for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Atibuclimab for respiratory insufficiency | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aviptadil for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aviptadil for respiratory insufficiency | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Awake prone positioning for respiratory distress syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Awake prone positioning for respiratory insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Azithromycin for respiration disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Azithromycin for respiratory insufficiency | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Azithromycin 250 mg x3/week (3 tablets/week) + Hydroxychloroquine + Prednisone for lung diseases, interstitial | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BC006 for idiopathic pulmonary fibrosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Belimumab for lung diseases, interstitial | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Belumosudil 200 mg QD for pulmonary fibrosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Benralizumab for pulmonary disease, chronic obstructive | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Berobenatide for dyspnea | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bersiporocin for idiopathic pulmonary fibrosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CAL101 for idiopathic pulmonary fibrosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Caspofungin for lung diseases, interstitial | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Caspofungin for respiratory aspiration | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cenicriviroc for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cenicriviroc for respiratory insufficiency | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| clonal fetal MSCs for pulmonary disease, chronic obstructive | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CM326 dose 1 + CM326 dose 2 for pulmonary disease, chronic obstructive | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Colchicine 0.5 mg for pulmonary fibrosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Control for respiration disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| COVID-19 CONVALESCENT PLASMA for lung diseases, interstitial | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cpap for respiratory insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CPAP + Dexamethasone for respiratory insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Curcumin for laryngostenosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cyclosporine for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cyclosporine for respiratory insufficiency | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CYP Cocktail + ZIPALERTINIB for lung diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cyproheptadine for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cyproheptadine for respiratory insufficiency | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Depemokimab for pulmonary disease, chronic obstructive | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dexamethasone for bronchopulmonary dysplasia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dexamethasone for respiratory insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dexamethasone. Dart for bronchopulmonary dysplasia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DIAG723 for pulmonary arterial hypertension | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dornase alfa for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dornase alfa for respiratory insufficiency | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dry Powder Inhaler + inhaled mosliciguat for lung diseases, interstitial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| EIT-Group for respiratory distress syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ENDS (Vaporizer/e-cig) and smoking cessation counseling for lung diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ENDS (Vaporizer/e-cig) and smoking cessation counseling for respiration disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Epidural spinal cord stimulation for respiratory insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Exercise for respiration disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Famotidine + Celecoxib for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Famotidine + Celecoxib for respiratory insufficiency | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| FAPi-46 GA-68 for pleural diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Favipiravir for respiration disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GSK3862995B for bronchiectasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GSK5784283 for nasal polyps | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GSK5784283 for paranasal sinus diseases | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HB0056 for idiopathic pulmonary fibrosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HFA-152a + Norflurane for bronchial spasm | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hfno for respiratory insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HFNO + Dexamethasone for respiratory insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HSK44459 for idiopathic pulmonary fibrosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hydroxychloroquine for respiratory distress syndrome | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hydroxychloroquine for respiratory insufficiency | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hydroxychloroquine + azithromycin + / - tocilizumab for respiratory insufficiency | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hydroxychloroquine Pill + Azithromycin Pill for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hydroxychloroquine sulfate for lung diseases | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hydroxychloroquine Sulfate + Azythromycin for lung diseases | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ibuprofen for respiratory distress syndrome | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Icatibant for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Icatibant for respiratory insufficiency | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Imatinib Mesylate for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Imatinib Mesylate for respiratory insufficiency | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Intermittent prone positioning instructions for respiratory insufficiency | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketoprofen for pneumothorax | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LEAF-4L6715 for respiratory distress syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mechanical ventilation with the automated BVM compressor for respiratory insufficiency | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mefloquine for respiratory insufficiency | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mefloquine + azithromycin + / - tocilizumab for respiratory insufficiency | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| myTAP oral appliance plus mouth shield for mouth breathing | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Nalbuphine for chronic cough | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Narsoplimab for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Narsoplimab for respiratory insufficiency | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Nintedanib for epistaxis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Oral Appliances for mouth breathing | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Oxymetazoline for nasal obstruction | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Pembrolizumab + lenvatinib for lung diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Petosemtamab for laryngeal diseases | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prolonged Proned Positioning for respiratory insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prone decubitus for respiratory distress syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prone Position for acute lung injury | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prone Position for respiratory aspiration | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prone Position for respiratory distress syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| prone positioning for respiratory distress syndrome | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prone Positioning (PP) for respiratory distress syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Prone Positioning (PP) for respiratory insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Proning for respiratory insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Quality-of-Life Assessment + Questionnaire Administration + Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine for pulmonary disease, chronic obstructive | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Rentosertib for idiopathic pulmonary fibrosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ROC-101 for lung diseases, interstitial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ROC-101 for pulmonary arterial hypertension | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semaglutide for pulmonary disease, chronic obstructive | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sildenafil Citrate for dyspnea | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sildenafil Citrate for pulmonary disease, chronic obstructive | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy + Volume Modulated Arc Therapy + NIVOLUMAB + IPILIMUMAB for laryngeal diseases | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy + Volume Modulated Arc Therapy + NIVOLUMAB + IPILIMUMAB for lung diseases, interstitial | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Solizmestrocel for bronchopulmonary dysplasia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Solizmestrocel for respiratory distress syndrome | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Taladegib for idiopathic pulmonary fibrosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tozorakimab for pulmonary disease, chronic obstructive | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 6 |
| TQC2731 injection for pulmonary disease, chronic obstructive | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Transporter Cocktail + ZIPALERTINIB for lung diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Treprostinil for pulmonary arterial hypertension | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Treprostinil for pulmonary disease, chronic obstructive | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Treprostinil palmitil for pulmonary arterial hypertension | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tulisokibart for lung diseases, interstitial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| UC-MSC and Secretome for respiratory distress syndrome | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VMD-928 100 mg Tablet for laryngeal diseases | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VMD-928 100 mg Tablet for tracheal diseases | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VMD-928 Tablet and Pembrolizumab (200 mg) for laryngeal diseases | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VMD-928 Tablet and Pembrolizumab (200 mg) for tracheal diseases | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Wharton's jelly derived Mesenchymal stem cells. for respiratory distress syndrome | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zipalertinib for lung diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |